RxDoctor Payments Data

Samer Khouri, MD

Cardiovascular Disease · Toledo, OHNPI 1285628313

Payments from drug & device makers

What this record shows

Abbott accounts for 78.4% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $1,842, 9.1 times the $201 reported in 2019.

$4,191in general payments, 2019–2025

Across 46 payments — averaging $91.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Musculoskeletal Transplant Foundation Inc.$182
  • Boston Scientific$181
  • Novo Nordisk$115
  • Heartflow, Inc.$75
  • Lifenet Health$56
  • plus $295 from 9 others
$307,369in research payments, 2019–2025

Across 79 payments — averaging $3890.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$261K
  • Boehringer Ingelheim International GmbH$27K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$11K
  • United Therapeutics Corporation$8K
  • Actelion Pharmaceuticals, Ltd$700
  • Actelion Pharmaceuticals US, Inc.$235

What the payments were for

  • Travel & lodging$2,21753%
  • Food & beverage$1,97447%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,191 in reported general payments places this provider in the 70th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$176,647
Medicare patients
1,878
Services billed
4,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan20$257,961
UptraviSelexipag13$170,087
AdempasRiociguat11$159,570
EliquisApixaban139$132,588
Ambrisentan24$29,879
FarxigaDapagliflozin Propanediol35$29,058
EntrestoSacubitril/Valsartan34$27,950
XareltoRivaroxaban19$25,741
Tadalafil26$18,191
Bosentan11$13,772
Praluent PenAlirocumab22$10,758
Enoxaparin Sodium24$3,412
Atorvastatin Calcium221$2,865
Metoprolol Succinate221$2,844
Bumetanide49$2,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$132,588139 claims
NovartisEntresto$41$27,95034 claims
Johnson & JohnsonXarelto$54$25,74119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →